News Column

Researchers from Lady Hardinge Medical College Discuss Findings in Tuberculosis (Bedaquiline for the treatment of resistant tuberculosis: Promises...

August 13, 2014



Researchers from Lady Hardinge Medical College Discuss Findings in Tuberculosis (Bedaquiline for the treatment of resistant tuberculosis: Promises and pitfalls)

By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Mycobacterium Infections. According to news reporting originating in New Delhi, India, by NewsRx journalists, research stated, "Treatment of multidrug-resistant tuberculosis (MDR-TB) is hindered by limited efficacy and significant toxicity of second-line drugs. The need for new therapeutic options is critical to combat the global MDR-TB epidemic."

The news reporters obtained a quote from the research from Lady Hardinge Medical College, "Bedaquiline is a novel oral diarylquinoline approved by Food and Drug administration (FDA) for the treatment of adults with pulmonary MDR-TB on the basis of Phase lib trial data under the provisions of the accelerated approval regulations for serious or life-threatening conditions. The FDA advisory committee members voted unanimously on efficacy data based on surrogate measures, however they were split on the issues of safety of bedaquiline. Main safety concerns include QT interval prolongation, hepatic related adverse events, and excess mortality in bedaquiline treated patients. While bedaquiline approval is a story of many firsts and certainly a welcome addition to the existing arsenal of anti-TB agents, a cautiously optimistic approach is required to assess the risk benefit profile of the drug. Acceleration of further Phase III trials and clinical studies is imperative, as is timely analysis of emerging data on the real world use of the drug."

According to the news reporters, the research concluded: "This mini review outlines the clinical pharmacology of bedaquiline highlighting the potential promises and challenges that implicate the risk benefit profile of drug."

For more information on this research see: Bedaquiline for the treatment of resistant tuberculosis: Promises and pitfalls. Tuberculosis, 2014;94(4):357-362. Tuberculosis can be contacted at: Churchill Livingstone, Journal Production Dept, Robert Stevenson House, 1-3 Baxters Place, Leith Walk, Edinburgh EH1 3AF, Midlothian, Scotland. (Elsevier - www.elsevier.com; Tuberculosis - www.elsevier.com/wps/product/cws_home/638428)

Our news correspondents report that additional information may be obtained by contacting A.K. Kakkar, Lady Hardinge Med Coll & Hosp, Dept. of Prevent & Social Med, New Delhi, India (see also Mycobacterium Infections).

Keywords for this news article include: Asia, India, New Delhi, Infectious Disease, Gram-Positive Bacteria, Mycobacterium Infections, Actinomycetales Infections, Mycobacterium Tuberculosis

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters